Medvedev, Vice Chairman of the Security Council of the Russian Federation: If Ukraine understands today's reality and takes into account Putin's proposal, Russia is ready to resume negotiations with Ukraine.Punto Casa de Bolsa upgraded AMD to Buy with a target price of $170.22.Bitcoin rose 5.00% in the day and is now reported at $101,492/piece.
The FTSE A50 index closed down 0.01% at 13,475 points in a row.Market News: EU officials are worried about the impact on broadcasting and streaming media.According to the medical report, Brazilian President Lula is still in the intensive care unit after undergoing brain surgery, and he will undergo another operation on Thursday morning local time.
Dongcheng Pharmaceutical's equity distribution plan for the first three quarters: 0.5 yuan will be paid a cash dividend for every 10 shares. Dongcheng Pharmaceutical (002675) announced on the evening of December 12 that the company's equity distribution plan for the first three quarters of 2024 is: based on the total share capital of 825 million shares on September 30, 2024, all shareholders will be paid a cash dividend of 0.5 yuan (including tax) for every 10 shares, totaling 41,229,800 yuan.Brazilian President Lula will undergo surgery again on the 12th. On the 11th local time, according to the latest announcement issued by the hospital, Brazilian President Lula will undergo surgery again on the morning of the 12th local time. Earlier in the day, the Syrian-Lebanese Hospital in Sao Paulo, Brazil released the latest report, saying that President Lula is "conscious and clear-headed, and can have a normal conversation". At present, a drainage tube is still placed at Lula's surgical site, waiting for further examination. Lula had no postoperative complications and was in good condition. On the evening of the 9th local time, Lula was sent to this hospital for surgery due to intracranial hemorrhage.Morgan Stanley upgraded the rating of Jingao Technology to over-allocation, with a target price of RMB 27.36. Tongwei shares will be upgraded to overweight with a target price of RMB 39.53.
Strategy guide
12-13
Strategy guide 12-13